{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:40:02Z","timestamp":1750419602445,"version":"3.41.0"},"reference-count":41,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016117","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T10:59:49Z","timestamp":1750417189000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical lifitegrast therapy for dry eye disease"],"prefix":"10.1002","volume":"2025","author":[{"given":"Lama","family":"Assi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; Louisiana State University Health Sciences Center; New Orleans USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim C.","family":"Lutfallah","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; Louisiana State University Health Sciences Center; New Orleans USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsz Wing","family":"Yim","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Anschutz Medical Campus; Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Hsun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Anschutz Medical Campus; Aurora Colorado USA"},{"name":"Department of Epidemiology; University of Colorado Anschutz Medical Campus; Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon J","family":"Duffy","sequence":"additional","affiliation":[{"name":"Division of Libraries; Louisiana State University Health Sciences Center; New Orleans USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; Louisiana State University Health Sciences Center; New Orleans USA"},{"name":"Department of Pathology; Louisiana State University Health Sciences Center; New Orleans USA"},{"name":"Department of Pharmacology and Experimental Therapeutics; Louisiana State University Health Sciences Center; New Orleans USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD016117-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocular Surface"},{"key":"10.1002\/14651858.CD016117-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/OPTH.S188314","article-title":"Dry eye disease ranking among common reasons for seeking eye care in a large US claims database","volume":"13","author":"Bradley","year":"2019","journal-title":"Clinical Ophthalmology (Auckland, N.Z.)"},{"issue":"12","key":"10.1002\/14651858.CD016117-BIB0003|cit3","first-page":"1499\u2013505","article-title":"Demographic and psychiatric associations with dry eye in a medicare population","volume":"43","author":"Gavin","year":"2024","journal-title":"Cornea"},{"issue":"5","key":"10.1002\/14651858.CD016117-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/09286586.2022.2131834","article-title":"Racial and ethnic disparities in dry eye diagnosis and care","volume":"30","author":"Cui","year":"2022","journal-title":"Ophthalmic Epidemiology"},{"key":"10.1002\/14651858.CD016117-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jtos.2021.05.006","article-title":"The physical and mental burden of dry eye disease: a large population-based study investigating the relationship with health-related quality of life and its determinants","volume":"21","author":"Morthen","year":"2021","journal-title":"Ocular Surface"},{"issue":"3","key":"10.1002\/14651858.CD016117-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vision-related quality of life","volume":"143","author":"Miljanovi\u0107","year":"2007","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD016117-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocular Surface"},{"key":"10.1002\/14651858.CD016117-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"251584141987036","DOI":"10.1177\/2515841419870366","article-title":"Lifitegrast: a novel drug for patients with dry eye disease","volume":"11","author":"Haber","year":"2019","journal-title":"Therapeutic Advances in Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD016117-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jtos.2016.01.001","article-title":"Lifitegrast, a novel integrin antagonist for treatment of dry eye disease","volume":"14","author":"Perez","year":"2016","journal-title":"Ocular Surface"},{"issue":"4","key":"10.1002\/14651858.CD016117-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/0976-500X.195920","article-title":"Lifitegrast: a novel drug for treatment of dry eye disease","volume":"7","author":"Abidi","year":"2016","journal-title":"Journal of Pharmacology & Pharmacotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD016117-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"543\u20139","DOI":"10.1089\/jop.2018.0047","article-title":"Suppression of Th1-mediated keratoconjunctivitis sicca by lifitegrast","volume":"34","author":"Guimaraes de Souza","year":"2018","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD016117-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1167\/iovs.09-5078","article-title":"The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs","volume":"52","author":"Murphy","year":"2011","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD016117-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1021\/ml2002482","article-title":"Discovery and development of potent LFA-1\/ICAM-1 antagonist SAR1118 as an ophthalmic solution for treating dry eye","volume":"3","author":"Zhong","year":"2012","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"10","key":"10.1002\/14651858.CD016117-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1167\/iovs.09-5144","article-title":"Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)","volume":"51","author":"Vidhya","year":"2010","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD016117-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/jop.2009.0105","article-title":"Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults","volume":"27","author":"Semba","year":"2011","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD016117-BIB0016|cit16","unstructured":"FDA approves new medication for dry eye disease www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-dry-eye-disease"},{"key":"10.1002\/14651858.CD016117-BIB0017|cit17","unstructured":"European Medicines Agency (EMA) Withdrawal of application for the marketing authorisation of Xiidra (lifitegrast) www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-and-answers-withdrawal-application-marketing-authorisation-xiidra_en.pdf"},{"key":"10.1002\/14651858.CD016117-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/OPTH.S296510","article-title":"Real-world experience with lifitegrast ophthalmic solution (Xiidra\u00ae) in the US and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease","volume":"15","author":"Hovanesian","year":"2021","journal-title":"Clinical Ophthalmology (Auckland, N.Z.)"},{"issue":"1","key":"10.1002\/14651858.CD016117-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaophthalmol.2023.5751","article-title":"Interventions for dry eye: an overview of systematic reviews","volume":"142","author":"McCann","year":"2024","journal-title":"JAMA Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD016117-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD016117-BIB0021|cit21","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews (MECIR). Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016117-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016117-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Reeves BC Deeks JJ Higgins JPT Shea B Tugwell P Chapter 24: Including non-randomized studies on intervention effects (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch24"},{"key":"10.1002\/14651858.CD016117-BIB0024|cit24","unstructured":"Drugs www.fda.gov\/drugs"},{"key":"10.1002\/14651858.CD016117-BIB0025|cit25","unstructured":"EndNote Clarivate 2020"},{"key":"10.1002\/14651858.CD016117-BIB0026|cit26","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD016117-BIB0027|cit27","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD016117-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD016117-BIB0029|cit29","unstructured":"Higgins JPT Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (last updated August 2023). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016117-BIB0030|cit30","unstructured":"Deeks JJ Higgins JPT Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (last updated November 2024). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016117-BIB0031|cit31","unstructured":"Page MJ Higgins JPT Sterne JAC Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis [last updated August 2024]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016117-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Chapter 9: Summarizing study characteristics and preparing for synthesis (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch9"},{"key":"10.1002\/14651858.CD016117-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch12"},{"issue":"1","key":"10.1002\/14651858.CD016117-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","article-title":"Minimal clinically important difference for the ocular surface disease index","volume":"128","author":"Miller","year":"2010","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD016117-BIB0035|cit35","unstructured":"Cochrane Methods Equity Group Sex\/Gender Methods Group https:\/\/methods.cochrane.org\/equity\/sex-and-gender-analysis"},{"key":"10.1002\/14651858.CD016117-BIB0036|cit36","unstructured":"Kavanagh J Oliver S Lorenc T Reflections on developing and using PROGRESS-Plus. CHEF Newsletter; Equity Update Available at https:\/\/methods.cochrane.org\/sites\/methods.cochrane.org.equity\/files\/uploads\/Equity_Update_Vol2_Issue1.pdf 2008 2 1 1 & 3"},{"key":"10.1002\/14651858.CD016117-BIB0037|cit37","unstructured":"World Bank Country and Lending Groups Available from https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"10.1002\/14651858.CD016117-BIB0038|cit38","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016117-BIB0039|cit39","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016117-BIB0040|cit40","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"issue":"10","key":"10.1002\/14651858.CD016117-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaophthalmol.2018.3352","article-title":"Research questions and outcomes prioritized by patients with dry eye","volume":"136","author":"Saldanha","year":"2018","journal-title":"JAMA Ophthalmology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T10:59:55Z","timestamp":1750417195000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016117"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016117","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}